HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa.

The HIV-1 reverse transcriptase genes from 37 HIV-1-positive pregnant women attending an antenatal clinical in Soweto, South Africa were sequenced and analyzed for the presence of drug resistance mutations. All women were antiretroviral drug naive, but were being screened as potential participants in clinical trials of antiretroviral drugs aimed at preventing mother-to-child transmission. Sequence analysis revealed that all belonged to HIV-1 subtype C, the predominant subtype among heterosexual populations in South Africa. Twenty-three amino acid loci associated with resistance to zidovudine, lamivudine, didanosine, stavudine, and nevirapine were examined and found not to encode mutations that would confer resistance to these drugs. Polymorphisms at these loci occurred infrequently, with three patients harboring the A98S and V179I polymorphisms. An additional three patients harbored V118I, which can function as an accessory resistance mutation, but in this context is also likely to be a polymorphism. These data show that pregnant women who are candidates for receiving antiretroviral drug therapies do not contain naturally occurring or preexisting drug resistance mutations and that such drug therapies are likely to be highly effective in this setting.

[1]  J. Schapiro,et al.  Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C , 2004, AIDS.

[2]  M. Peeters,et al.  Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials , 2003, AIDS.

[3]  L. Morris,et al.  Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine , 2003, AIDS.

[4]  F. Kasolo,et al.  Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. , 2003, AIDS research and human retroviruses.

[5]  P. Musoke,et al.  Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study). , 2001, The Journal of infectious diseases.

[6]  Zehava Grossman,et al.  Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B , 2001, AIDS.

[7]  Matthew J. Gonzales,et al.  Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs , 2001, Nucleic Acids Res..

[8]  L. Mofenson,et al.  Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission , 2000, AIDS.

[9]  L. Mofenson,et al.  Advances and research directions in the prevention of mother-to-child HIV-1 transmission , 2000, The Lancet.

[10]  L. Ping,et al.  No evidence for naturally occurring mutations resistant to HIV-1 reverse-transcriptase inhibitors among South African HIV-1 subtype C isolates , 2000 .

[11]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[12]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[13]  J. Karon,et al.  Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial , 1999, The Lancet.

[14]  D. Katzenstein,et al.  Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe , 1997, Journal of virology.

[15]  D. Richman,et al.  Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. , 1994, AIDS research and human retroviruses.